Evaluating the Efficacy of ERG Targeted Therapy In Vivo for Prostate Tumors
Abstract
The proposed research will examine the suitability of ERG as a target for prostate cancer therapy by using novel modular inducible transgenic mice. Prostate cancer is a large health problem in the United States. Recent efforts to classify distinct molecular subtypes of prostate cancer have shown that >50% of prostate cancers possess a chromosomal translocation involving the ERG oncogene. I hypothesized that ERG can serve as an effective molecular therapeutic target for prostate tumors. I planned to show this with novel autochthonous prostate tumor mouse models. During this second year of support we have not been able to been able to adhere to the timeline of our Statement of Work - Task#2 - Determine if ERG cooperates with AKT1 for prostate tumorigenesis (months 14-34). We were previously successful at completing the tasks for Task#1 - Generate and characterize an inducible ERG prostate specific mouse model (months 1-17), but our characterization of ERG expression from our prostate inducible mouse model did not demonstrate any detectable prostate specific ERG expression at the protein level. Data from another project using the ARR2PB-tTA line has lead us to believe that the level of expression from the ARR2PB-tTA line is low and perhaps insufficient for the in vivo experiments described in our proposal. We are now planning to pursue the Hoxb13-rtTA mouse line allows for much more robust expression of tetO target genes in the mouse prostate.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2013
- Accession Number
- ADA579691
Entities
People
- Phuoc T. Tran
Organizations
- Johns Hopkins University